Sitting on a Pile of Cash 2.0? A Pharma with Strong Risk Benefits

Sitting on a Pile of Cash 2.0? A Pharma with Strong Risk Benefits

$MEIP MEI Pharma Inc. (NASDAQ:MEIP): this is an exponential Northside call, the sector analysts sees it having a best-in-class PI3Kδ inhibitor, which has demonstrated strong risk-benefit profile in Phase 1 lymphoma trials. MEIP broke out on 6 April and has confirmed it Bull move, the Support is Strong at 2.53 and the Resistance is NIL, […]

Johnson & Johnson (NYSE:JNJ) Faces Huge Competition

Johnson & Johnson (NYSE:JNJ) Faces Huge Competition

Johnson & Johnson (NYSE:JNJ) Faces Huge Competition U.S. pharma giant Merck  and partner Samsung Bioepis are trying to take a big cut of Johnson & Johnson’s drug revenues. The companies have begun to market their “biosimilar” (a generic version of expensive biologic drugs) of Remicade—a copycat of J&J’s best-selling rheumatoid arthritis and immunology treatment (which […]